ethyl 2-(pyridin-2-yl)-cyclopropanecarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 2-(pyridin-2-yl)-cyclopropanecarboxylate
• 英文别名: ethyl (1S,2S)-2-pyridin-2-ylcyclopropane-1-carboxylate
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: FLUXXOZZARUHSQ-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(pyridin-2-yl)-cyclopropanecarboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium aluminium tetrahydride 、 (R)-(-)-1-[(S)-2-(二环己基膦)二茂铁]乙基二叔丁基膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine
  参考文献：
  名称：

  Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia

  摘要：

  Herein, we present the identification of a novel class of pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitors. Beginning with a lead molecule (1) identified through a fragment-based drug discovery (FBDD) effort, lead optimization was enabled by rational design, X-ray crystallography, metabolic and off-target profiling, and fragment scaffold-hopping. We highlight the discovery of PyP-1, a potent, highly selective, and orally bioavailable pyrazolopyrimidine inhibitor of PDE10A. PyP-1 exhibits sub-nanomolar potency (PDE10A K-i = 0.23 nM), excellent pharmacokinetic (PK) and physicochemical properties, and a clean off-target profile. It displays dose-dependent efficacy in numerous pharmacodynamic (PD) assays that measure potential for anti-psychotic activity and cognitive improvement. PyP-1 also has a clean preclinical profile with respect to cataleptic potential in rats, prolactin secretion, and weight gain, common adverse events associated with currently marketed therapeutics. Further, PyP-1 displays in vivo preclinical target engagement as measured by PET enzyme occupancy in concert with [C-11]MK-8193, a novel PDE10A PET tracer. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.11.013
• 作为产物：
  描述：

  ethyl 2-(phenylsulfanyl)cyclopropane-1-carboxylate 在 异丙基氯化镁 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.17h， 生成 ethyl 2-(pyridin-2-yl)-cyclopropanecarboxylate
  参考文献：
  名称：

  通过钴催化苯基乙烯基硫醚的环丙烷化反应不同合成含环丙烷的类铅化合物、片段和结构单元

  摘要：

  环丙烷为药物化学提供了重要的设计元素，并广泛存在于药物化合物中。在这里，我们描述了一种策略和广泛的合成研究，用于利用单一前体制备多种含环丙烷的类铅化合物、片段和结构单元。双官能环丙烷（E/Z）-乙基2-（苯硫基）-环丙烷-1-羧酸酯的设计允许通过酯和硫醚官能团衍生化为拓扑变化的化合物，旨在适应药物发现所需的化学空间。苯基乙烯基硫醚的钴催化环丙烷化反应可提供多克规模的支架。通过水解、还原、酰胺化和氧化反应以及亚砜-镁交换/功能化实现发散正交衍生化。由亚砜交换形成的环丙基格氏试剂在 0 °C 下稳定> 2 小时，这使得能够捕获各种亲电子试剂和 Pd 催化的 Negishi 交叉偶联反应。使用 LLAMA（先导化合物和分子分析）软件对亲脂性 (ALog P)、分子量和分子形状参数对制备的文库以及进一步的虚拟阐述进行分析，以说明生成先导化合物的成功化合物和片段。

  DOI：

  10.1002/ejoc.201701030

文献信息

• One-pot approach for the synthesis of trans-cyclopropyl compounds from aldehydes. Application to the synthesis of GPR40 receptor agonists
  作者：Michaël Davi、Hélène Lebel

  DOI：10.1039/b810708d

  日期：——

  A novel multicatalytic one-pot process providing trans-cyclopropyl compounds from corresponding aldehydes has been developed and applied to the synthesis of GPR40 small molecule agonists.

  已开发出一种新的多催化一锅法，该方法可从相应的醛中提供反式环丙基化合物，并将其应用于GPR40小分子激动剂的合成。
• Cobalt(II)-based Metalloradical Activation of 2-(Diazomethyl)pyridines for Radical Transannulation and Cyclopropanation
  作者：Satyajit Roy、Sandip Kumar Das、Buddhadeb Chattopadhyay

  DOI：10.1002/anie.201711209

  日期：2018.2.19

  A new catalytic method for the denitrogenative transannulation/cyclopropanation of in‐situ‐generated 2‐(diazomethyl)pyridines is described using a cobalt‐catalyzed radical‐activation mechanism. The method takes advantage of the inherent properties of a CoIII‐carbene radical intermediate and is the first report of denitrogenative transannulation/cyclopropanation by a radical‐activation mechanism, which

  介绍了一种利用钴催化的自由基活化机理对原位生成的2-（重氮甲基）吡啶进行脱氮环转移/环丙烷化的新催化方法。该方法利用了Co III-卡宾自由基中间体的固有性质，并且是通过自由基激活机制进行脱氮脱环/环丙烷化的第一篇报道，并得到了各种控制实验的支持。（±）-单morine的总合成时间短，证明了金属-金属法的综合优势。
• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2013028590A1

  公开（公告）日：2013-02-28

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• Reactivity of [1,2,3]Triazolo[1,5-a]pyridines as 1,3-dipoles
  作者：Rosa Adam、Shamim Alom、Belén Abarca、Rafael Ballesteros

  DOI：10.1016/j.tet.2016.11.006

  日期：2016.12

  We have studied the reactions between [1,2,3]Triazolo[1,5-a]pyridines 1a,b,c and electron-deficient ethylenes in different conditions. Compounds 1a and 1b react with ethyl propiolate, and dimethyl acetylene dicarboxylate giving a new class of biaryl compounds pyridyl pyrazoles, and with ethyl acrylate giving pyridyl cyclopropanes. Compound 1c did not give any product in the studied conditions. A proposal

  我们研究了[1,2,3]三唑并[1,5- a ]吡啶1a，b，c与缺电子的乙烯在不同条件下的反应。化合物1a和1b与丙酸乙酯和乙炔二甲酸二甲酯反应，得到一类新的联芳基化合物吡啶基吡唑，与丙烯酸乙酯反应，得到吡啶基环丙烷。在研究的条件下，化合物1c没有得到任何产物。提出了这些反应的机理的建议，其中三唑并吡啶用作1，3-偶极，产生1，3-偶极环加成。
• PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS
  申请人：Cox Christopher D.

  公开号：US20130137707A1

  公开（公告）日：2013-05-30

  The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及吡唑并嘧啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神障碍，如精神分裂症、精神病或亨廷顿病，以及与纹状体低功能或基底节功能障碍相关的疾病。